Jose Enrique Martínez Rodriguez

Jose Enrique Martínez Rodriguez

Auto-generated profile, based on publicly available information

Jose Enrique Martínez Rodriguez

Neurology Department, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2005 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
AIAlex Iranzo
Alex Iranzo
Francesc GrausFrancesc Graus
Francesc Graus
LCLinda Clover
Linda Clover
JMJaume Morera
Jaume Morera
JBJordi Bruna
Jordi Bruna
JSJoan Santamaría
Joan Santamaría

1 August 2001 in The American Journal of Medicine
Verified
Journal Article
Closed access
JMJose E Martínez-Rodríguez
Jose E Martínez-Rodríguez
FBFrancisco J Barriga
Francisco J Barriga
JSJoan Santamaria
Joan Santamaria
AIAlejandro Iranzo
Alejandro Iranzo
JPJuan A Pareja
Juan A Pareja
CRCarmen R Dela Rosa
Carmen R Dela Rosa

1 May 2003 in SLEEP
Verified
Journal Article
Open access
PDF file
JMJose E. Martínez-Rodríguez
Jose E. Martínez-Rodríguez
LLLing Lin
Ling Lin
AIAlex Iranzo
Alex Iranzo
DGDavid Genis
David Genis
MMMaria J. Martí
Maria J. Martí
EMEmmanuel Mignot
Emmanuel Mignot
Myotonic dystrophy type 1 is a multisystem disorder with myotonia, muscle weakness, cataracts, endocrine dysfunction, and intellectual impairment. This disorder is caused by a CTG triplet expansion in the 3′ untranslated region of the DMPK gene on 19q13. Myotonic dystrophy type 1 is frequently associated with excessive daytime sleepiness, sharing with narcolepsy a short sleep latency and the presence of sleep-onset rapid eye movement periods during the Multiple Sleep Latency Test. Since narcolepsy is characterized by a dysfunction of the hypothalamic hypocretin system, we investigated whether patients with myotonic dystrophy type 1 with excessive daytime sleepiness have abnormalities in the hypocretin system. Six patients with myotonic dystrophy type 1 complaining of excessive daytime sleepiness and 13 healthy controls without a sleep disorder were included. The patients with myotonic dystrophy type 1 were evaluated using clinical interviews, nocturnal polysomnograms, and Multiple Sleep Latency Tests. All patients had a confirmed genetic diagnosis for DM1 and were HLA typed. Cerebrospinal fluid hypocretin-1 levels were measured using a direct radioimmunoassay in patients and controls. University hospital sleep laboratory. N/A. The mean sleep latency on Multiple Sleep Latency Tests was abnormal in all patients (<5 minutes in 2, ≤8 in 4) and 2 sleep-onset rapid eye movement periods were observed in 2 subjects. All patients were HLA-DQB1*0602 negative. Hypocretin-1 levels were significantly lower in patients versus controls (p<0.001); 1 case with 2 sleep-onset rapid eye movement periods had hypocretin-1 levels in the range generally observed in narcolepsy (<110 pg/mL). Three cases had intermediate levels (110–200 pg/mL). Hypocretin-1 levels did not correlate clinically with disease severity or duration or with subjective or objective sleepiness reports. A dysfunction of the hypothalamic hypocretin system may mediate sleepiness and abnormal Multiple Sleep Latency Test results in patients with myotonic dystrophy type 1.

23 January 2008 in Cerebrovascular Diseases
Verified
Journal Article
Closed access
AOAngel Ois
Angel Ois
JMJose E. Martinez-Rodriguez
Jose E. Martinez-Rodriguez
EMElvira Munteis
Elvira Munteis
MGMeritxell Gomis
Meritxell Gomis
ARAna Rodríguez-Campello
Ana Rodríguez-Campello
JRJaume Roquer
Jaume Roquer
Aim: To evaluate the influence that steno-occlusive arterial disease may have on the development of early neurological deterioration (END) in a large series of patients with acute ischemic stroke. Methods: We studied a prospective cohort of 1,093 patients admitted to a single tertiary hospital with presence of neurological symptoms in the first 24 h after stroke onset. END was defined as any increase in the National Institutes of Health Stroke Scale score ≧4 points in the first 72 h. The arterial study assessed the presence of arterial occlusion or significative stenosis in the symptomatic territory. Additionally, age, initial stroke severity, blood pressure, glucose levels, vascular risk factors, lacunar stroke and prior use of antithrombotic treatment were also analyzed in a multivariable analysis. Results: END was detected in 179 patients (16.3%). Steno-occlusive disease (adjusted OR 3.60), initial blood pressure and abdominal obesity were independently associated with END. Both arterial stenosis (adjusted OR 2.33) or occlusions (adjusted OR 3.65) were associated with END. The higher adjusted OR (5.49) was obtained for steno-occlusive arterial disease in the vertebrobasilar system. Conclusions: An early arterial study may provide key data for the selection of patients with higher risk of END after acute ischemic stroke.

1 December 2011 in Clinical Immunology
Verified
Journal Article
Closed access
JMJ.E. Martínez-Rodríguez
J.E. Martínez-Rodríguez
MLM. López-Botet
M. López-Botet
EME. Munteis
E. Munteis
JRJ. Rio
J. Rio
JRJaume Roquer
Jaume Roquer
Manuel ComabellaManuel Comabella
Manuel Comabella

7 May 2009 in Genes & Immunity
Verified
Journal Article
Closed access
DOD Ordóñez
D Ordóñez
ASA J Sánchez
A J Sánchez
JMJ E Martínez-Rodríguez
J E Martínez-Rodríguez
ECE Cisneros
E Cisneros
ERE Ramil
E Ramil
CVC Vilches
C Vilches